Expanded Access Programs
Our team participates in several expanded access or compassionate use programs that aim to give patients access to innovative treatments that have been proven to be safe and effective but are not yet approved due to bureaucratic procedures. Compassionate use treatments can be available to groups of patients or to a single patient (named patient program) at the request and sole responsibility of the patients’ attending physician, after approved by the National Organization for Medicines (EOF).
The compassionate use programs that are currently available are the following:
The practice also has access to the Novo TTF – 100A device, an FDA approved but still investigational in Europe for the treatment of patients with glioblastoma. Clinical trials of the device show that this method may increase the length of time until disease progression compared to standard therapy although these results are not yet fully validated. Of note, this device is meant for home use.
Unfortunately, the TTF – 100A cannot be sponsored so the patient has to be aware of its costs before the treatment. If a patient or his/her family is interested they should request further information.